Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher's AI Network Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results